728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads

Invictus MD Provides Update on ACMPR Sales License Amendment as it Prepares for Legalization

THIS POST WAS ORIGINALLY PUBLISHED ON THIS SITE Click Here To Read Entire Article

VANCOUVER, Nov. 27, 2017 /PRNewswire/ – INVICTUS MD STRATEGIES CORP. (“Invictus MD” or the “Company”) (TSXV: IMH; OTC: IVITF; FRA: 8IS1), through its interests in two Access to Cannabis for Medical Purposes Regulations (“ACMPR“) license holders, its wholly-owned subsidiary Acreage Pharms Ltd. (“Acreage Pharms“) and its one-third interest in AB Laboratories Inc. (“AB Labs“), continues to execute plans that will achieve production capacity of 6,000 kg commencing January 2018, several months before Canada expects cannabis to become recreationally legal. Total current annual production capacity at both locations is approximately 1,500 kg.

Acreage Pharms is on schedule to complete its 32,000 square foot (phase 2) expansion by January 2018. Once completed total production capacity of Acreage Pharms is expected to reach 5,000 kg annually. (CNW Group/Invictus MD Strategies)

As announced on October 27, 2017, Health Canada had removed previously disclosed production capacity restrictions at both Acreage Pharms and AB Labs.

Update on Sales Approval

Both Acreage Pharms and AB Labs have submitted formal requests to Health Canada to amend its License to allow for the sale and distribution of medical cannabis. The issuance of the Amendment is subject to, among other things, a regulatory inspection of Acreage Pharms’ and AB Labs’ production facilities and cannot be guaranteed by the Company. However, the Company is confident that both facilities are compliant with all necessary requirements, that they will pass the required inspection, and that the Amendment will be issued in due course. The Pre-Sales License Inspection is the last step prior to the issuance of a Sales License under the ACMPR.

Update on Production

Acreage Pharms and AB Labs facility are currently at full production with a total combined capacity of approximately 1,500 kg annually.

Acreage Pharms recently completed its 6th harvest, and the yield increased by 30% over the prior harvest from the same room as a result of improved plant spacing and activation of the nutrient delivery system. The facility continues to grow completely pesticide free and the purpose built facility is out performing management’s expectations for Good Production Practices and over all production values.

Update on Construction

Acreage Pharms is on schedule to complete its 32,000 square foot (phase 2) expansion by January 2018. Once completed total production capacity of Acreage Pharms is expected to reach 5,000 kg annually.

Management commentary

“I am

About The Author

Related posts

Leave a Reply

Your email address will not be published. Required fields are marked *